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SHORT ABSTRACT:  
The most commonly used method for nanostructured lipid carrier (NLC) synthesis involves oil-
in-water emulsion, homogenization and solidification. This was modified here by applying high 
shear dispersion after solidification to achieve a NLC with desirable size, improved drug 
encapsulation and drug loading efficiency as a potential carrier for dacarbazine delivery.  
 
LONG ABSTRACT:  
The only formula of dacarbazine (Dac) in clinical use is intravenous infusion, presenting a poor 
therapeutic profile due to the low dispersity of the drug in aqueous solution. To overcome this, 
a nanostructured lipid carrier (NLC) consisting of glyceryl palmitostearate and isopropyl 
myristate was developed to encapsulate Dac. NLCs with controlled size were achieved using 
high shear dispersion (HSD) following solidification of oil-in-water emulsion. The synthesis 
parameters, including surfactant concentration, the speed and time of HSD were optimized to 
achieve the smallest NLC with size, polydispersion index and zeta potential of 155±10 nm, 
0.2±0.01, and -43.4±2 mV, respectively. The optimal parameters were also employed for Dac-
loaded NLC preparation. The resultant NLC loaded with Dac possessed size, polydispersion 
index and zeta potential of 190±10 nm, 0.2±0.01, and -43.5±1.2 mV, respectively. The drug 
encapsulation efficiency and drug loading reached 98% and 14%, respectively. This is the first 
report on encapsulation of Dac using NLC, implying that NLC could be a new potential candidate 
as drug carrier to improve the therapeutic profile of Dac.  
 
INTRODUCTION:  
   
Dacarbazine (Dac) is an alkylating agent that exerts anti-tumor activity through nucleic acids 
methylation or direct DNA damage, leading to cell cycle arrest and cell death 1.  
 
As a first line chemotherapeutic agent, Dac has been used alone or in combination with other 
chemotherapy drugs for treating various cancers 2-6. It is the most active agent so far used in 
treating cutaneous and metastatic melanoma, which is the most aggressive form of skin cancer 
3, 7, 8. The response rate, however, is only 20% at best, and the therapeutic effects are often 
accompanied with severe systemic side effects.  
 
In its natural form, Dac is hydrophilic and is unstable due to its photosensitivity 9. The only 
available formula for clinical use currently is a sterile powder to be used in suspension for 
intravenous infusion 7, 8. The low response rate and high systemic toxicity rate of the drug is 
largely attributable to its poor water solubility, therefore low availability at target site, and high 
distribution at non-target sites, which limits the maximum dose of the drug 10. The rapid 
degradation and metabolism after intravenous admission together with the development of 
drug resistance limit the clinical application and therapeutic effect of the drug 11. Therefore, 
there is an urgent need to develop alternative Dac formulations for treating malignant 
melanoma.  
 
Colloidal systems containing liposomes, micelles or nanostructured particles have been 
intensively investigated for their use in drug delivery as reviewed by Marilene et al. 12. 
Nanostructured particles as potential drug carriers have been attracting increasing attention in 
the last decade due to their ability to increase drug loading efficiency, control drug release, 
improve drug pharmacokinetics and biodistribution, and therefore reduce drug systemic 
toxicity 13. Only a few nanoformulations, however, have been investigated so far for Dac 
delivery, showing protection of the drug from photo degeneration, increased drug solubility, 
and improved therapeutic effect 10, 14, , 15. However these formulations suffered from low 
encapsulating efficiency while some also using synthetic polymer nanoparticles that are not 
cost effective.   
 
Nanostructured lipid carriers (NLC), made of a mixture of solid and liquid lipids, have been 
developed for drug delivery 16, 17. The drugs to be encapsulated are often soluble in both the 
liquid lipids and solid lipids phases 18, resulting in a high loading and controlled release 19. This 
study aims to develop a new Dac formulation based on NLC-encapsulation using glyceryl 
palmitostearate and isopropyl myristate as lipids. The preparation involved oil-in-water 
emulsion, evaporation, solidification, and homogenization. The preparations have been 
characterized for NLC size, shape, ultrastructure, and dispersity, drug encapsulation efficiency 
and drug loading 20.  
  
 PROTOCOL:  
 
1. Preparation of oil-in-water emulsion 
 
1.1) Weigh glyceryl palmitostearate (120 mg), isopropyl myristate (60 mg), d-α-tocopheryl 
   
polyethylene glycol succinate (30 mg) and soybean lecithin (30 mg), and add them to 12.5 mL of 
organic solvents (6.25 mL acetone and 6.25 mL ethanol). Quickly dissolve the mixture at the 
temperature 70 oC (5 oC above the melting point of the solid lipid) in water bath.  
 
1.2) Add either 125, 250 or 375 mg of Poloxamer188 in 12.5 mL of ddH2O to achieve 1-3% 
(respectively) of Poloxamer 188 solution, which is subject to heating at the same temperature 
as above.  
 
1.3) Add the aqueous phase solution from step 1.2 to the oil phase solution from step 1.1 
dropwise to form emulsions under magnetic stirring at 400 rpm . Stir the emulsion at 400 rpm 
for another 4 h to allow evaporation of the organic solvents.  
 
2. Solidification and homogenization  
 
2.1) Leave the emulsion in a cold room (4 oC) for 2 h to solidify/crystallize.  
 
2.2) To obtain NLC, subject the emulsion to high sheer dispersion (HSD) with a homogenizer at 
10000-15000 rpm for 10- 40 min.  
 
3 Optimization of the NLC preparation  
 
3.1) Take samples from step 2.2 with a surfactant concentration of 1, 2 and 3% undergoing HSD 
at speeds of 10000, 15000 and 20000 rpm, respectively, and time intervals of 10, 20, 30 and 40 
min, respectively, 
 
3.2) Examine the samples for particle size (PS), poly dispersion index (PDI), morphology and 
ultrastructure 20.  
 
Note: The parameters that produce particles with the smallest size (155 nm) and PDI (0.2) value 
are determined as optimal.  
 
4. Preparation of Dac-loaded NLC (NLC-Dac)  
 
4.1) Prepare oil phase solution as described in step 1.1 with the addition of Dac (70 mg) before 
dissolving the mixture at 70 oC in water bath. 
 
4.2) Prepare an aqueous phase solution as described in step 1.2 with 1% surfactant, and add 
this solution to that prepared in step 4.1 dropwise to form an emulsion under magnetic stirring 
at 400 rpm. Stir the emulsion for further 4 h to evaporate the organic solvents. 
 
4.3) Leave the emulsion in a cold room (4 oC) for 2 h to solidify/crystallize as described in step 2, 
and finally, subject the emulsion to high sheer dispersion (HSD) using the optimal parameters 
determined in step 3. 
 
   
REPRESENTATIVE RESULTS:  
The preparations of the NLC and NLC-Dac using glyceryl palmitostearate and isopropyl 
myristate with different parameters were characterized for PS, PDI, morphology and 
ultrastructure 20. The PS and PDI of the NLCs were surfactant concentration, HSD speed and 
duration dependent. As judged by PS and PDI of the NLCs, the best results were achieved with 
1% of surfactant and a sheer dispersion speed of 15000 rpm for 30 min (Figure 1 A, B and C), 
which therefore wwew selected as the optimal parameters for NLC preparation in this study.  
 
[place Figure 1 here] 
 
The optimal parameters were used for NLC-Dac preparation. The smallest size achieved was 
150±10 nm for NLC (Figure 2 A) and 190±10 nm for NLC-Dac (Figure 2 B), both with PDI of 
0.2±0.001, indicating a good uniformity. 
 
 [place Figure 2 here] 
 
Both NLC and NLC-Dac showed a spherical shape as observed under TEM (Figure 3).  
 
[place Figure 3 here] 
 
The uploading and encapsulation of Dac in NLC is indicated by the size and structure changes as 
seen in Figures 2 and 3 where NLC-Dac shows a larger size and altered internal structures as 
compared with NLC. The basic structure of NLC comprises a surfactant layer, a liquid lipid 
matrix and solid lipid crystals (Figure 3 A). NLC-Dac also exhibited the basic structure as a NLC 
but with expanded surfactant layer, liquid lipid matrix and solid lipid crystals, together with an 
extra substructure inside the solid lipid crystals (Figure 3 B), indicative of drug loading and 
encapsulation. The solid lipid crystals seen in NLC appeared denser than that in NLC-Dac, 
indicating that the solid lipid is less crystallized in NLC-Dac.  
 
The drug encapsulation efficiency (EF) and drug loading (DL) percentage were derived from the 
following equations: 
EE% =W1 - W2/W1 X 100=98.5% 
DL% =W1 - W2/W3 X 100=14%  
where W1 amount of Dac added in the NLC, W2 amount of un-entrapped Dac, W3 amount of the 
lipids added 20. 
 
Figure 1: Optimization of parameters used in NLC preparation. The optimal surfactant 
concentration and the speed and time of HSD were determined according to their effect on PS 
and PDI. A. Effect of surfactant concentration on PS; B. Effect of HSD speed and time on PS; C. 
Effect of HSD speed and time on PDI. This Figure has been modified from 20 . The data are 
presented as mean value of 3 replicates ± standard deviation (mean ±SD).  
 
Figure 2: DLS measurement of NLC. A. The optimal size distribution of plain NLC; B. the optimal 
size distribution of NLC-Dac.  
   
 
Figure 3: TEM imaging of NLC and NLC-Dac. Both NLC and NLC-Dac showed a spherical shape. 
A. Basic NLC structure comprises a surfactant layer (solid black arrow), liquid lipid matrix (white 
solid arrow), and solid lipid crystals (dotted white arrows); B. NLC-Dac also exhibited the basic 
structure as seen in NLC but the surfactant layer, liquid lipid matrix and solid lipid crystals 
appeared expanded; an extra substructure could be seen inside the solid lipid crystals 
(indicated by dotted black arrows), indicative of drug loading. Bar scale: 50 nm, Magnification: x 
55000. This Figure has been modified from 20.  
 
DISCUSSION:  
Lipid-based nanostructured particles have been utilized to provide a highly lipophilic carrier for 
delivery of hydrophobic drugs. A NLC is the second generation of solid lipid nanostructured 
carrier, which are solid at room and body temperature. The incorporation of a solid lipid into a 
liquid lipid in a NLC results in a less perfect crystallization, thus increasing the drug loading 
efficiency and also reducing the expulsion of encapsulated drugs during storage.  
 
For NLC synthesis, the most commonly used method involves oil-in-water emulsion, 
homogenization and solidification/crystallization 21, 22. The homogenization allows NLCs to 
disperse thoroughly in an aqueous phase, whilst the solidification at low temperature allows 
the inner oil phase to crystallize. Different homogenization methods have been reported 
including magnetic stirring, ultrasonication, and HSD that are used before and/or during 
solidification 23 24.  
 
In this study, the commonly used method was initially followed for NLC preparation. As the 
result was unsatisfactory, the method was modified such that HSD was applied after 
solidification. This modification proved highly effective in particle generation, PS and PDI 
control, while also making the NLC synthesis simpler, compared with previous reports on NLC 
preparation using the same lipids 23 25. It was worth noting that the length of the evaporation 
(protocol 1.3) and solidification (protocol 2.1) is very critical as too long or too short a time 
would have negative effects on the generation of NLC.  
 
This study suggests that NLC particles and their aggregation were formed during solidification. 
The HSD could disrupt the aggregation, which was possibly due to hydrophobic interaction 
between NLCs, and also stabilize the particles by thoroughly remixing them with surfactant. The 
synthesis procedure was optimized such that the NLC and NLC-Dac were produced with a size 
155 ±10 nm and 190 ± 10 nm, respectively, and a PDI of 0.2±0.01. The high level of uniformity 
with particle sizes and the small PDI values indicates that a sufficient dispersion energy was 
achieved and is well distributed within the solution for disruption of particle aggregates. It has 
been suggested that particles of 100–200 nm are not prone to uptake by non-targeted cells, 
including mononuclear phagocytic system, thus having a long blood circulation time in vivo 26 27, 
whilst a PDI of more than 0.5 is an indication of particle aggregation 28; the lower the PDI value, 
the higher the size homogeneity between the particles 29. Further increase of the HSD speed 
and time above the optimal point could result in further PS reduction, and consequently an 
increase in interactions between small particles as well as re-aggregation. The difference in size 
   
and structure between NLC and NLC-Dac suggests that the Dac loading and encapsulation was 
successful. The drug binding to the outer layer of the NLC and encapsulation inside lipid 
matrices provide the potential for prolonged drug release, that could involve drug release firstly 
from the outer layer, followed by the release from the liquid lipid matrix and then from the 
solid lipid crystals of the NLC 30.  
 
Currently four nanoformulations have been attempted for delivery of Dac as a single agent. The 
latest formulation reported was designed for duel encapsulation of Dac and vitamin A 32. 
However these formulations suffered from a low encapsulation efficiency and/or relatively 
complex synthesis procedures. This is the first report for encapsulation of Dac with a NLC, 
proving advantageous over other encapsulations reported previously. NLC-Dac is easy to make 
and presents higher drug encapsulation and drug loading efficiency 20. The NLC-Dac showed 
nearly 50% of drug released within the first 2 h whilst the remaining released slowly for up to 
30 h 20. The early release could be due to the binding of the drug with surfactant layer on the 
surface of the NLC, indicating that this formulation may not be ideal to replace the formulation 
currently in clinical use. However the drug in NLC-Dac appeared more stable compared with the 
nanoemulsion reported previously 10. In addition, lipid based vehicles have been proposed for 
treating cutaneous melanoma and epidermoid carcinoma through topical drug delivery 32 10, 
indicating that the NLC-Dac developed in this study could also be potentially beneficial for 
topical application where early drug release would not potentially lead to severe systemic 
toxicity.  
 
Due to the collective limitations with the available drug delivery carriers developed so far, 
further research is needed to develop more advanced nanomaterials for Dac delivery for 
targeted cancer treatment.  
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